Interestingly, HIF-1α is recently being pursued as a potential target of PDAC treatment as chemoresistant pancreatic cancer cells were shown to exhibit increased glycolysis [168], which is partly regulated by HIF-1α [169]. This evidence concerns the gene HIF1A and familial pancreatic carcinoma.